Glucose-6-phosphate gehydrogenase (G6PD) deficiency in nonarteritic anterior ischemic optic Nnuropathy in a sardinian population, Italy

Investigative Ophthalmology and Visual Science

Volumn 49, Issue 4, 2008, Pages 1328-1332

  Pinna, Antonio ^a,b   Solinas, Giuliana ^a   Masia, Carlo ^a   Zinellu, Angelo ^b   Carru, Ciriaco ^b   Carta, Arturo ^c  

^a Institute of Clinical Biochemistry   (Italy)

^b UNIVERSITY OF SASSARI   (Italy)

^c UNIVERSITY OF PARMA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; GLUCOSE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE;

ADULT; ARTICLE; CELL ACTIVITY; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; ENZYME BLOOD LEVEL; ERYTHROCYTE MEMBRANE; FEMALE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; GLUCOSE BLOOD LEVEL; HUMAN; ISCHEMIC OPTIC NEUROPATHY; ITALY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; BLOOD; CASE CONTROL STUDY; ENZYMOLOGY; HYPERCHOLESTEROLEMIA; METABOLISM; MIDDLE AGED; RISK FACTOR;

CASE-CONTROL STUDIES; CHOLESTEROL; ERYTHROCYTE MEMBRANE; FEMALE; GLUCOSEPHOSPHATE DEHYDROGENASE; GLUCOSEPHOSPHATE DEHYDROGENASE DEFICIENCY; HUMANS; HYPERCHOLESTEROLEMIA; ITALY; MALE; MIDDLE AGED; OPTIC NEUROPATHY, ISCHEMIC; RISK FACTORS;

EID: 45549105748     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.07-1115     Document Type: Article

References (45)

1. Kletzien RF, Harris PKW, Foellmi LA. Glucose-6-phosphate dehydrogenase: a "housekeeping" enzyme subject to tissue-specific regulation by hormones, nutrients, and oxidant stress. FASEB J. 1994;8:174-181.
2. Beutler E. G6PD deficiency. Blood. 1994;84:3613-3636.
3. Martinez di Montemuros F, Dotti C, Tavazzi D, Fiorelli G, Cappel-lini MD. Molecular heterogeneity of glucose-6-phosphate dehydrogenase (G6PD) variants in Italy. Haematologica. 1997;82:440-445.
4. Maida A, Pettinato S, Bo G. Clinical manifestations of favism and G6PD deficiency: epidemiological survey in the province of Sassari (Sardinia, Italy). Haematologica. 1973;58:1265-1282.
5. Cocco P, Todde P, Fornera S, Manca MB, Manca M, Sias AR. Mortality in a cohort of men expressing the glucose-6-phosphate dehydrogenase deficiency. Blood. 1998;91:706-709.
6. Batetta B, Bonatesta RR, Sanna F, et al. Cell growth and cholesterol metabolism in human glucose-6-phosphate dehydrogenase deficient lymphomononuclear cells. Cell Prolif. 2002;35:143-154.
7. Pinna A, Carru C, Solinas G, Zinellu A, Carta F. Glucose-6-phos-phate dehydrogenase deficiency in retinal vein occlusion. Invest Ophthalmol Vis Sci. 2007;48:2747-2752.
8. Johnson LN, Arnold AC. Incidence of nonarteritic and arteritic anterior ischemic optic neuropathy. J Neuro-Ophthalmol. 1994; 14:38-44.
9. Hattenhauer MG, Leavitt JA, Hodge DO, Grill R, Gray DT. Incidence of nonarteritic ischemic optic neuropathy. Am JOphthal-mol. 1997;123:103-107.
10. Hayreh SS, Joos KM, Podhajsky PA, Long CR. Systemic diseases associated with nonarteritic anterior ischemic optic neuropathy. Am JOphthalmol. 1994;118:766-780.
11. Deramo VA, Sergott RC, Augsburger JJ, Foroozan R, Savino PJ, Leone A. Ischemic optic neuropathy as the first manifestation of elevated cholesterol levels in young patients. Ophthalmology. 2003;110:1041-1045.
12. Clayton D, Hills M, eds. Statistical Models in Epidemiology. Oxford, UK: Oxford University Press; 1993.
13. Salomon O, Huna-Baron R, Kurtz S, et al. Analysis of prothrombotic and vascular risk factors in patients with nonarteritic ischemic optic neuropathy. Ophthalmology. 1999;106:739-742.
14. Talks SJ, Chong NH, Gibson JM, Dodson PM. Fibrinogen, cholesterol and smoking as risk factors for nonarteritic anterior ischemic optic neuropathy. Eye. 1995;9:85-88.
15. WHO Working Group. Glucose-6-phosphate dehydrogenase deficiency. Bull World Health Organ. 1989;67:601-611.
16. Ruwende C, Hill A. Glucose-6-phosphate dehydrogenase deficiency and malaria. JMol Med. 1998;76:581-588.
17. Siniscalco M, Bernini L, Latte B, Motulski AG. Favism and thalasse-mia and their relationship to malaria. Nature. 1961;190:1179-1180.
18. Luzzatto L, Notaro R. Malaria. Protecting against bad air. Science. 2001;293:442- 443.
19. Ischemic Optic Neuropathy Decompression Trial Group. Characteristics of patients with nonarteritic ischemic optic neuropathy eligible for the Ischemic Optic Neuropathy Decompression Trial. Arch Ophthalmol. 1996;114:1366-1374.
20. Hayreh SS, Jonas JB, Zimmerman MB. Nonarteritic anterior ischemic optic neuropathy and tobacco smoking. Ophthalmology. 2007;114:804-809.
21. Jacobson DM, Vierkant RA, Belongia EA. Nonarteritic ischemic optic neuropathy: a case-control study of potential risk factors. Arch Ophthalmol. 1997;115:1403-1407.
22. Hayreh SS. Anterior ischemic optic neuropathy. VIII. Clinical features and pathogenesis of post-hemorrhagic amaurosis. Ophthalmology. 1987;94:1488-1502.
23. Hayreh SS, Zimmerman MB, Podhajsky P, Alward WL. Nocturnal arterial hypotension and its role in optic nerve head and ocular ischemic disorders. Am J Ophthalmol. 1994;117:603-624.
24. Hayreh SS, Podhajsky PA, Zimmerman B. Nonarteritic anterior ischemic optic neuropathy: time of onset of visual loss. Am J Ophthalmol. 1997;124:641-647.
25. Hayreh SS. Risk factors in AION. Ophthalmology. 2001;108:1717-1718.
26. Beck RW, Savino PJ, Repka MX, Schatz NJ, Sergott RC. Optic disc structure in anterior ischemic optic neuropathy. Ophthalmology. 1984;91:1334-1337.
27. Doro S, Lessel S. Cup-disc ratio and anterior ischemic optic neuropathy. Arch Ophthalmol. 1985;103:1143-1144.
28. Beck RW, Servais GE, Hayreh SS. Anterior ischemic optic neuropathy. IX. Cup-to-disc ratio and its role in pathogenesis. Ophthalmology. 1987;94:1503-1508.
29. Arnold AC. Pathogenesis on nonarteritic anterior ischemic optic neuropathy. JNeuro-ophthalmol. 2003;23:157-163.
30. Casu A, Pascutto C, Bernardinelli L, Songini M. Type 1 diabetes among Sardinian children is increasing. Diabetes Care. 2004;27: 1623-1629.
31. Ministero della Salute. Diabete: una patologia in netto aumento. Available at: http://www.ministerosalute.it/dettaglio/pdPrimoPiano. jsp?id=107&sub=1&lang=it. Accessed October 29, 2007.
32. Bienzle U, Lucas AO, Ayeni O, Luzzato L. Glucose-6-phosphate dehydrogenase and malaria: greater resistance of females heterozygous for enzyme deficiency and of males with non-deficient variant. Lancet. 1972;1:107-110.
33. Ruwende C, Khoo SC, Snow RW, et al. Natural selection of hemi-and heterozygotes for G6PD deficiency in Africa by resistance to severe malaria. Nature. 1995;376:246-249.
34. Meloni T, Carta F, Forteleoni G, Carta A, Ena F, Meloni GF. Glucose 6-phosphate dehydrogenase deficiency and cataract of patients in Northern Sardinia. Am J Ophthalmol. 1990;110:661-664.
35. Rao KN. The significance of cholesterol biosynthesis pathway in cell growth and carcinogenesis (review). Anticancer Res. 1995; 15:309-314.
36. Wink DA, Nims RW, Darbyshire JF, et al. Reaction kinetics for nitrosation of cysteine and glutathione in aerobic nitric oxide solutions at neutral pH. Insights into the fate and physiological effects of intermediates generated in the NO/O2 reaction. Chem Res Toxicol. 1994;7:519 -525.
37. Myers PR, Minor RL, Guerra R, Bates JN, Harrison DG. Vasorelax-ant properties of the endothelium-derived relaxing factor more closely resemble S-nitrosocysteine than nitric oxide. Nature. 1990; 345:161-163.
38. Lewis SJ, Hashmi-Hill MP, Owen JR, Sandock K, Robertson TP, Bates JN. The vasodilator potency of the endothelium-derived relaxing factor, L-S-nitrosocysteine, is impaired in conscious pontaneously hypertensive rats. Vasc Pharmacol. 2006;44: 476-490.
39. Wink DA, Hanbauer I, Krishna MC, DeGraff W, Gamson J, Mitchell JB. Nitric oxide protects against cellular damage and cytotoxicity from reactive oxygen species. Proc Natl Acad Sci USA. 1993;90: 9813-9817.
40. Chang CC, Liao YS, Lin YL, Chen RM. Nitric oxide protects osteo-blasts from oxidative stress-induced apoptotic insults via a mitochondria-dependent mechanism. J Orthop Res. 2006;24:1917- 1925.
41. Hogg N, Kalyanaraman B, Joseph J, Struck A, Parthasarathy S. Inhibition of low-density lipoprotein oxidation by nitric oxide: potential role in atherogenesis. FEBS Lett. 1993;334:170-174.
42. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: physiology, patho-physiology, and pharmacology. Pharmacol Rev. 1991;43:109 -142.
43. Moncada S, Higgs EA. The discovery of nitric oxide and its role in vascular biology. Br J Pharmacol. 2006;147(suppl 1):S193-S201.
44. Hayreh SS. Retinal and optic nerve head ischemic disorders and atherosclerosis: role of serotonin. Prog Retin Eye Res. 1999;18: 191-221.
45. Hayreh SS, Piegors DJ, Heisted DD. Serotonin-induced constriction of ocular arteries in atherosclerotic monkeys. Arch Ophthalmol. 1997;115:220-228.